MENU
MAY 19 - 21 2020

Advancing Science - A Virtual Oncology Conference

New technologies are enabling discoveries that advance our understanding of how tumors develop, evade the immune system, and progress.  This virtual conference brings together research professionals, scientists, and clinicians from around the world to learn and discuss recent advances in cancer research with a focus on biomarker discovery, immuno-oncology and clinical applications across all cancer types.

Plenary Sessions:

  • Carl June, MD, Director of the Center for Cellular Immunotherapies at the Perleman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania
  • Paolo Ascierto, MD, Director, IRCCS Instituto Nazionale Tumori Fondazione G Pascale

Scientific tracks:

  • Immuno-Oncology
  • Biomarker Discovery
  • Spatial Biology
  • Clinical Applications

This free online event allows you to participate in a global setting with no travel or cost to you. The event will remain open for twelve months from the date of the live event. 


Speakers

Show Resources
Agenda
  • MAY 20, 2020 1:15 PM EDT | APAC MAY, 21 2020 5:15 PM CST
    Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells & CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment...
    Jan Davidson, MD, PhD
    Director of Clinical Development and Research at MacroGenics, Inc.
  • MAY 20, 2020 1:15 PM EDT | APAC MAY, 21 2020 5:15 PM CST
    GeoMx® Protein Offerings: Fully validated antibodies to meet your spatial profiling needs
    Jenny Cronin, PhD
    Associate Product Manager, NanoString Technologies
  • MAY 20, 2020 12:45 PM EDT | APAC MAY 21, 2020 3:45 PM CST
    Comparison of PAM50 Intrinsic Subtype Profiles in Matched Primary & stage IV Breast Cancer Samples from CTC-MBC Trial Shows Shift Towards More Aggressive Subtypes Throughout Tumor Progression
    Lisa Ryden, MD, PhD
    Professor i Kirurgi, Lund University, Medical Faculty, dept of Clinical Sciences Lund, div of Oncology and Surgery
  • MAY 20, 2020 12:45 PM EDT | APAC MAY 21, 2020 3:45 PM CST
    Molecular and Immunologic Profiling of CD8+ T Cell Responses in Patients Receiving a Multiple Antigen-Engineered Dendritic Cell Vaccine
    Juraj Adamik, PhD
    Research Scientist, Parker Institute for Cancer Immunotherapy
  • MAY 20, 2020 11:45 AM EDT | APAC MAY 21, 2020 2:45 PM CST
    Immune Infiltration Correlates of TP53 Mutational Status in Acute Myeloid Leukemia
    Sergio Rutella, MD, PhD, FRCPath
    Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University
  • MAY 20, 2020 11:45 AM EDT | APAC MAY 21, 2020 2:45 PM CST
    Lung Cancer Gene Fusion Assays using NanoString® nCounter® Technology
    Noemi Reguart, MD, PhD
    Thoracic Oncology Consultant, Hospital Clínic de Barcelona
  • MAY 20, 2020 11:15 AM EDT | APAC MAY 21, 2020 2:15 PM CST
    Primary Results of SOLTI-1402/CORALLEEN Phase 2 Trial of Neoadjuvant Ribociclib Plus Letrozole Versus Chemotherapy in PAM50 Luminal B Early Breast Cancer
    Aleix Prat, MD, PhD
    Head Medical Oncology Department, Hospital Clinic of Barcelona, Head Translational Genomics & Targeted Therapeutics in Solid Tumors Group, Hospital Clinic of Barcelona
  • MAY 20, 2020 11:15 AM EDT | APAC MAY 21, 2020 2:15 PM CST
    Spatial Landscape of the Immune Microenvironment in Metastatic Prostate Cancer using GeoMx™ Digital Spatial Profiler
    Peter Nelson, MD
    Professor of Medicine at the University of Washington
  • MAY 20, 2020 11:00 AM EDT | APAC MAY 21, 2020 2:00 PM CST
    Advances in Immuno-oncology
    MODERATOR: Peggy Sotiropoulou, PhD
    Director of Research & Development, Celyad
  • MAY 20, 2020 11:00 AM EDT | APAC MAY 21, 2020 2:00 PM CST
    Leveraging Signatures in the Clinical Setting
    MODERATOR: Aleix Prat, MD, PhD
    Head Medical Oncology Department, Hospital Clinic of Barcelona, Head Translational Genomics & Targeted Therapeutics in Solid Tumors Group, Hospital Clinic of Barcelona
  • MAY 20, 2020 10:15 AM PDT
    Comparison of PAM50 Intrinsic Subtype Profiles in Matched Primary and Metastatic Breast Cancer Samples from the CTC-MBC Trial (NCT01322893) Shows a Significant Shift Towards More Aggressive..
    Lisa Ryden, MD, PhD
    Professor i Kirurgi, Lund University, Medical Faculty, dept of Clinical Sciences Lund, div of Oncology and Surgery
  • MAY 20, 2020 10:00 AM EDT | APAC MAY 21, 2020 1:00 PM CST
    How COVID-19 has Changed an Immuno-oncologist's Life: from Optimizing Daily Practice to the Targeted Treatment of Cytokine Storm
    PLENARY: Paolo Ascierto, MD
    Director, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
  • MAY 19, 2020 1:45 PM EDT | APAC MAY 20, 2020 4:45 PM CST
    Cancer Transcriptome Atlas with NGS Readout - The essential tool for spatial genomics in oncology
    Kit Fuhrman, PhD
    GeoMX RNA Product Manager, NanoString Technologies
  • MAY 19, 2020 1:45 PM EDT | APAC MAY 20, 2020 4:45 PM CST
    Tumor Signaling 360 Panel: A 360° View of Altered Signaling Pathways in Cancer
    Erin Piazza, PhD
    Senior Bioinformatics Scientist, NanoString Technologies
  • MAY 19, 2020 1:15 PM EDT | APAC MAY 20, 2020 4:15 PM CST
    Immune Infiltration Influences the Survival of Pancreatic Cancer Patients
    Dana Mustafa, PhD
    Assistant Professor, Group Leader of the Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center
  • MAY 19, 2020 1:15 PM EDT | APAC MAY 20, 2020 4:15 PM CST
    Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology
    Anushka Dikshit, PhD
    Application Scientist - Advanced Cell Diagnostics
  • MAY 19, 2020 12:45 PM EDT | APAC MAY 20, 2020 3:45 PM CST
    Assessing Immune Biomarkers of Response to Anthracyclines in Breast Cancer
    Melanie Spears, PhD
    Principal Research Scientist at Ontario Institute for Cancer Research
  • MAY 19, 2020 12:45 PM EDT | APAC MAY 20, 2020 3:45 PM CST
    Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Therapy
    Arutha Kulasinghe, PhD
    Peter Doherty NHMRC Early Career Fellow at the Queensland University of Technology (QUT)
  • MAY 19, 2020 11:45 AM EDT | APAC MAY 20, 2020 2:45 PM CST
    Discovery of Biomarkers Associated with Benefit From PD-1 Checkpoint Blockade in Non-small-cell Lung Cancer (NSCLC) Using High-plex Digital Spatial Profiling
    Jon Zugazagoitia, MD, PhD
    Physician Scientist, Department of Medical Oncology, Lung Cancer Unit
  • MAY 19, 2020 11:45 AM EDT | APAC MAY 20, 2020 2:45 PM CST
    Single-nucleus and Spatial Transcriptomics of Archival Pancreatic Ductal Adenocarcinoma after Neoadjuvant Treatment
    William L. Hwang, MD, PhD
    Clinical Fellow in Radiation Oncology, Massachusetts General Hospital, Radiation Oncology
  • MAY 19, 2020 11:15 AM EDT | APAC MAY 20, 2020 2:15 PM CST
    A Multi-omic Single Cell and Spatial Atlas of Breast Cancer Reveals Stromal Suppression of Anti-Cancer Immunity
    Alex Swarbrick, PhD
    Associate Professor of Medicine at UNSW Sydney, NHMRC Senior Research Fellow and co-head of the Breast Translational Oncology Program in the Kinghorn Cancer Center, Sydney
  • MAY 19, 2020 11:15 AM EDT | APAC MAY 20, 2020 2:15 PM CST
    Digital Spatial Mapping of the Immune Landscape of Triple Negative Breast Cancer Reveals Novel Features of Immune-tumor Cell Interaction
    E. Aubrey Thompson, PhD
    Professor of Cancer Biology, Mayo Clinic Comprehensive Cancer Center
  • MAY 19, 2020 11:00 AM EDT | APAC MAY 20, 2020 2:00 PM CST
    Biomarker Discovery for Precision Medicine
    MODERATOR: Alessandra Cesano, MD, PhD
    Chief Medical Officer, ESSA Pharmaceuticals
  • MAY 19, 2020 11:00 AM EDT | APAC MAY 20, 2020 2:00 PM CST
    The Promise of Spatial Biology
    MODERATOR: Alex Swarbrick, PhD
    Associate Professor of Medicine at UNSW Sydney, NHMRC Senior Research Fellow and co-head of the Breast Translational Oncology Program in the Kinghorn Cancer Center, Sydney
  • MAY 19, 2020 10:00 AM EDT | APAC MAY 20, 2020 1:00 PM CST
    Applications in Biomarker Discovery and CAR T Therapy Using High-plex RNA & Protein Spatial Profiling on FFPE Tissue
    PLENARY: Carl June, MD
    Director of the Center for Cellular Immunotherapies, Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania
  • Plenary Session
  • MAY 19, 2020 10:00 AM EDT | APAC MAY 20, 2020 1:00 PM CST
    Applications in Biomarker Discovery and CAR T Therapy Using High-plex RNA & Protein Spatial Profiling on FFPE Tissue
    PLENARY: Carl June, MD
    Director of the Center for Cellular Immunotherapies, Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania
  • MAY 20, 2020 10:00 AM EDT | APAC MAY 21, 2020 1:00 PM CST
    How COVID-19 has Changed an Immuno-oncologist's Life: from Optimizing Daily Practice to the Targeted Treatment of Cytokine Storm
    PLENARY: Paolo Ascierto, MD
    Director, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
  • Spatial Biology Session
  • MAY 19, 2020 11:00 AM EDT | APAC MAY 20, 2020 2:00 PM CST
    The Promise of Spatial Biology
    MODERATOR: Alex Swarbrick, PhD
    Associate Professor of Medicine at UNSW Sydney, NHMRC Senior Research Fellow and co-head of the Breast Translational Oncology Program in the Kinghorn Cancer Center, Sydney
  • MAY 19, 2020 11:15 AM EDT | APAC MAY 20, 2020 2:15 PM CST
    A Multi-omic Single Cell and Spatial Atlas of Breast Cancer Reveals Stromal Suppression of Anti-Cancer Immunity
    Alex Swarbrick, PhD
    Associate Professor of Medicine at UNSW Sydney, NHMRC Senior Research Fellow and co-head of the Breast Translational Oncology Program in the Kinghorn Cancer Center, Sydney
  • MAY 19, 2020 11:45 AM EDT | APAC MAY 20, 2020 2:45 PM CST
    Single-nucleus and Spatial Transcriptomics of Archival Pancreatic Ductal Adenocarcinoma after Neoadjuvant Treatment
    William L. Hwang, MD, PhD
    Clinical Fellow in Radiation Oncology, Massachusetts General Hospital, Radiation Oncology
  • MAY 19, 2020 12:45 PM EDT | APAC MAY 20, 2020 3:45 PM CST
    Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Therapy
    Arutha Kulasinghe, PhD
    Peter Doherty NHMRC Early Career Fellow at the Queensland University of Technology (QUT)
  • MAY 19, 2020 1:15 PM EDT | APAC MAY 20, 2020 4:15 PM CST
    Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology
    Anushka Dikshit, PhD
    Application Scientist - Advanced Cell Diagnostics
  • MAY 19, 2020 1:45 PM EDT | APAC MAY 20, 2020 4:45 PM CST
    Cancer Transcriptome Atlas with NGS Readout - The essential tool for spatial genomics in oncology
    Kit Fuhrman, PhD
    GeoMX RNA Product Manager, NanoString Technologies
  • BioMarker Discovery Session
  • MAY 19, 2020 11:00 AM EDT | APAC MAY 20, 2020 2:00 PM CST
    Biomarker Discovery for Precision Medicine
    MODERATOR: Alessandra Cesano, MD, PhD
    Chief Medical Officer, ESSA Pharmaceuticals
  • MAY 19, 2020 11:15 AM EDT | APAC MAY 20, 2020 2:15 PM CST
    Digital Spatial Mapping of the Immune Landscape of Triple Negative Breast Cancer Reveals Novel Features of Immune-tumor Cell Interaction
    E. Aubrey Thompson, PhD
    Professor of Cancer Biology, Mayo Clinic Comprehensive Cancer Center
  • MAY 19, 2020 11:45 AM EDT | APAC MAY 20, 2020 2:45 PM CST
    Discovery of Biomarkers Associated with Benefit From PD-1 Checkpoint Blockade in Non-small-cell Lung Cancer (NSCLC) Using High-plex Digital Spatial Profiling
    Jon Zugazagoitia, MD, PhD
    Physician Scientist, Department of Medical Oncology, Lung Cancer Unit
  • MAY 19, 2020 12:45 PM EDT | APAC MAY 20, 2020 3:45 PM CST
    Assessing Immune Biomarkers of Response to Anthracyclines in Breast Cancer
    Melanie Spears, PhD
    Principal Research Scientist at Ontario Institute for Cancer Research
  • MAY 19, 2020 1:15 PM EDT | APAC MAY 20, 2020 4:15 PM CST
    Immune Infiltration Influences the Survival of Pancreatic Cancer Patients
    Dana Mustafa, PhD
    Assistant Professor, Group Leader of the Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center
  • MAY 19, 2020 1:45 PM EDT | APAC MAY 20, 2020 4:45 PM CST
    Tumor Signaling 360 Panel: A 360° View of Altered Signaling Pathways in Cancer
    Erin Piazza, PhD
    Senior Bioinformatics Scientist, NanoString Technologies
  • Immuno-Oncology Session
  • MAY 20, 2020 11:00 AM EDT | APAC MAY 21, 2020 2:00 PM CST
    Advances in Immuno-oncology
    MODERATOR: Peggy Sotiropoulou, PhD
    Director of Research & Development, Celyad
  • MAY 20, 2020 11:15 AM EDT | APAC MAY 21, 2020 2:15 PM CST
    Spatial Landscape of the Immune Microenvironment in Metastatic Prostate Cancer using GeoMx™ Digital Spatial Profiler
    Peter Nelson, MD
    Professor of Medicine at the University of Washington
  • MAY 20, 2020 11:45 AM EDT | APAC MAY 21, 2020 2:45 PM CST
    Immune Infiltration Correlates of TP53 Mutational Status in Acute Myeloid Leukemia
    Sergio Rutella, MD, PhD, FRCPath
    Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University
  • MAY 20, 2020 12:45 PM EDT | APAC MAY 21, 2020 3:45 PM CST
    Molecular and Immunologic Profiling of CD8+ T Cell Responses in Patients Receiving a Multiple Antigen-Engineered Dendritic Cell Vaccine
    Juraj Adamik, PhD
    Research Scientist, Parker Institute for Cancer Immunotherapy
  • MAY 20, 2020 1:15 PM EDT | APAC MAY, 21 2020 5:15 PM CST
    GeoMx® Protein Offerings: Fully validated antibodies to meet your spatial profiling needs
    Jenny Cronin, PhD
    Associate Product Manager, NanoString Technologies
  • Clinical Applications Session
  • MAY 20, 2020 11:00 AM EDT | APAC MAY 21, 2020 2:00 PM CST
    Leveraging Signatures in the Clinical Setting
    MODERATOR: Aleix Prat, MD, PhD
    Head Medical Oncology Department, Hospital Clinic of Barcelona, Head Translational Genomics & Targeted Therapeutics in Solid Tumors Group, Hospital Clinic of Barcelona
  • MAY 20, 2020 11:15 AM EDT | APAC MAY 21, 2020 2:15 PM CST
    Primary Results of SOLTI-1402/CORALLEEN Phase 2 Trial of Neoadjuvant Ribociclib Plus Letrozole Versus Chemotherapy in PAM50 Luminal B Early Breast Cancer
    Aleix Prat, MD, PhD
    Head Medical Oncology Department, Hospital Clinic of Barcelona, Head Translational Genomics & Targeted Therapeutics in Solid Tumors Group, Hospital Clinic of Barcelona
  • MAY 20, 2020 11:45 AM EDT | APAC MAY 21, 2020 2:45 PM CST
    Lung Cancer Gene Fusion Assays using NanoString® nCounter® Technology
    Noemi Reguart, MD, PhD
    Thoracic Oncology Consultant, Hospital Clínic de Barcelona
  • MAY 20, 2020 12:45 PM EDT | APAC MAY 21, 2020 3:45 PM CST
    Comparison of PAM50 Intrinsic Subtype Profiles in Matched Primary & stage IV Breast Cancer Samples from CTC-MBC Trial Shows Shift Towards More Aggressive Subtypes Throughout Tumor Progression
    Lisa Ryden, MD, PhD
    Professor i Kirurgi, Lund University, Medical Faculty, dept of Clinical Sciences Lund, div of Oncology and Surgery
  • MAY 20, 2020 10:15 AM PDT
    Comparison of PAM50 Intrinsic Subtype Profiles in Matched Primary and Metastatic Breast Cancer Samples from the CTC-MBC Trial (NCT01322893) Shows a Significant Shift Towards More Aggressive..
    Lisa Ryden, MD, PhD
    Professor i Kirurgi, Lund University, Medical Faculty, dept of Clinical Sciences Lund, div of Oncology and Surgery
  • MAY 20, 2020 1:15 PM EDT | APAC MAY, 21 2020 5:15 PM CST
    Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells & CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment...
    Jan Davidson, MD, PhD
    Director of Clinical Development and Research at MacroGenics, Inc.
Speakers

  • PLENARY: Paolo Ascierto, MD
    Director, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
    Biography
      Paolo A. Ascierto Director of the Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute, Naples, Italy. He obtained his medical degree from the University of Naples, the same institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumor Institute in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto's research interests include the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination strategies with I-O. He has been the Principal Investigator in over 80 clinical trials and is an active member in several international medical societies. He is a member of the Steering Committee of Society of Melanoma Research (SMR) since 2016, the board of Cancer Development Drug Forum (CDDF) since 2017, the Board of Directors of Society of Immuno Therapy of Cancer (SITC) since 2018, and President of the Fondazione Melanoma Onlus since 2010, and of Campania Society of ImmunoTherapy of Cancer (SCITO) since 2013. He is an active reviewer for several international journals including, NEJM, JCO, Lancet Oncology, and Clinical Cancer Research, as well as an Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, Chief Section Editor of Expert Reviews of Immunology Vaccines and Informatics, and Associate Editor of Journal of ImmunoTherapy of Cancer. He is the author of more than 300 publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Clinical Cancer Research, among others.
    • PLENARY: Carl June, MD
      Director of the Center for Cellular Immunotherapies, Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania
      Biography
        Carl June, MD, is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently director of the Center for Cellular Immunotherapies and director of Translational Research in the Abramson Cancer Center of the University of Pennsylvania, and is an investigator of the Abramson Family Cancer Research Institute. He is a graduate of the Naval Academy in Annapolis and Baylor College of Medicine in Houston, 1979. He had graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland in 1978 and 1979, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 to 1986. He is board certified in Internal Medicine and Medical Oncology. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings, which represented the first successful and sustained demonstration of the use of gene transfer therapy to treat cancer. Clinical trials utilizing this approach, in which patients are treated with genetically engineered versions of their own T-cells, are now underway for adults with chronic lymphocytic leukemia and adults and children with acute lymphoblastic leukemia. Early results in that group show that 90 percent of patients respond to the therapy, and more recently, trials of this approach have begun for patients with other blood cancers and solid tumors including pancreatic cancer, mesothelioma and the brain cancer glioblastoma. In 2014, it became the first personalized cellular therapy for the treatment of cancer therapy to receive the U.S. Food and Drug Administration's prestigious Breakthrough Therapy designation.
      • MODERATOR: Alessandra Cesano, MD, PhD
        Chief Medical Officer, ESSA Pharmaceuticals
        Biography
          Alessandra Cesano, MD, PhD has recently joined ESSA as Chief Medical Officer. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 100 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.
        • MODERATOR: Aleix Prat, MD, PhD
          Head Medical Oncology Department, Hospital Clinic of Barcelona, Head Translational Genomics & Targeted Therapeutics in Solid Tumors Group, Hospital Clinic of Barcelona
          Biography
            Aleix Prat, M.D., Ph.D. is the Head of the Medical Oncology Department of the Hospital Clínic Barcelona in Spain, Professor at the University of Barcelona and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Dr. Prat has been scientific coordinator of the Board of the Spanish Breast Cancer Cooperative Research Group (SOLTI) that oversees clinical trials. In 2018, he was named member of the Executive Board of The Breast International Group (BIG), a cooperative non-profit organization of more than 56 groups around the world including more than 10,000 experts and more than 3,000 hospitals. In May 2019, he became President of SOLTI. Dr. Prat has authored more than 200 publications, a total impact factor of 1.354 and H-index of 48 with over 14.500 citations. His main interest is to implement molecular biomarkers into the clinic by designing innovative clinical trials in breast cancer and other cancer-types. References: https://orcid.org/0000-0003-2377-540X, twitter @prat_aleix and Prat's lab website.
          • MODERATOR: Peggy Sotiropoulou, PhD
            Director of Research & Development, Celyad
            Biography
              Peggy Sotiropoulou joined Celyad in 2017. As Director of the R&D department, she leads a broad-ranging internal research program that aims to develop new strategies in CAR T cell design to target haematological and solid malignancies. Prior to Celyad, Peggy spent 17 years in Academic research in oncology. Before moving to industry, Peggy was associate Professor in the Université Libre de Bruxelles, in Brussels, Belgium, and published landmark papers in journals such as Nature and Nature Cell Biology. The aim of Peggy in Celyad is to translate cutting-edge research and innovation into actual treatments for patients.
            • MODERATOR: Alex Swarbrick, PhD
              Associate Professor of Medicine at UNSW Sydney, NHMRC Senior Research Fellow and co-head of the Breast Translational Oncology Program in the Kinghorn Cancer Center, Sydney
              Biography
                Alex graduated with a Bsc (Hons I) in Molecular and Cellular Biology from UNSW in 1995. After obtaining his PhD in 2003 he undertook postdoctoral training with Nobel laureate J. Michael Bishop at the University of California, San Francisco, supported by a CJ Martin Travelling Fellowship from the NHMRC. In 2008 Alex established the Tumour Progression Laboratory in the Garvan Institute and in 2012 was appointed co-Head of the Breast Translational Oncology Program in the newly commissioned Kinghorn Cancer Centre. Alex is an Associate Professor at UNSW and an NHMRC Senior Research Fellow. Alex is the convenor of the Lorne Cancer Conference, Australia's pre-eminent multi-disciplinary cancer research conference & the Australian Translational Breast & Prostate Cancer Symposium. He serves on the Cancer Research Committee of the Cancer Council NSW.
              • Juraj Adamik, PhD
                Research Scientist, Parker Institute for Cancer Immunotherapy
                Biography
                  Juraj Adamik, PhD, is a research scientist at PICI and visiting research associate at the Microbiology and Immunology Department at the University of California, San Francisco. Under the leadership of Dr. Lisa H. Butterfield, Adamik investigates the effectiveness of dendritic cell cancer vaccines in evoking T cell-specific responses to tumor antigens in melanoma and hepatocellular carcinoma. Prior to joining PICI, Adamik was a postdoctoral associate at the UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Division of Hematology/Oncology. He investigated transcriptional and epigenetic changes in bone marrow cellular compartments in the context of hematologic malignancies and metastatic breast cancer. During his PhD research at Duquesne University in Pittsburgh, Adamik's work contributed to a key discovery of Krebs Cycle metabolite succinate as an inflammatory danger signal regulating metabolic reprogramming of LPS-activated macrophages published in Nature.
                • Jenny Cronin, PhD
                  Associate Product Manager, NanoString Technologies
                  Biography
                    Jenny Cronin is an Associate Product Manager at NanoString Technologies, where she manages the GeoMx DSP protein portfolio. During her PhD research at the University of Washington, Jenny studied the neural response to electrical stimulation of the human cortex and how to encode sensory feedback through cortical stimulation for eventual use in neural rehabilitative devices. She also worked with the University's technology transfer office to assess the novelty and marketability of University innovations.
                  • Jan Davidson, MD, PhD
                    Director of Clinical Development and Research at MacroGenics, Inc.
                  • Anushka Dikshit, PhD
                    Application Scientist - Advanced Cell Diagnostics
                    Biography
                      Anushka Dikshit, Ph.D. is an Application Scientist with Advanced Cell Diagnostics with background in cancer research and immuno-oncology. She is focused on expanding the applications of RNAscope technology for oncology research. Prior to working for ACD, Anushka was involved in identifying novel therapeutic targets for melanoma as a postdoctoral fellow at Duke University. She obtained her doctoral degree from Southern Illinois University, School of Medicine in Molecular Physiology.
                    • Kit Fuhrman, PhD
                      GeoMX RNA Product Manager, NanoString Technologies
                      Biography
                        As a Scientist for NanoString, Kit Fuhrman has applied his understanding of immunology to solve challenging scientific problems by applying the power of the nCounter and GeoMx platforms. He developed the first 3D Flow protocols to digitally count both RNA and protein in a single tube from sorted populations. He now focuses his time building RNA applications for the Digital Spatial Profiling platform for morphology driven gene expression profiling. Kit received his Doctorate from University of Florida in immunology studying the role of regulatory T cells in type-1 diabetes pathogenesis and his Masters from the University of Central Florida directed design of HIV entry inhibitors.
                      • William L. Hwang, MD, PhD
                        Clinical Fellow in Radiation Oncology, Massachusetts General Hospital, Radiation Oncology
                        Biography
                          William L. Hwang is currently a Holman Research Fellow at the Broad Institute and Koch Institute for Integrative Cancer Research, as well as a Resident Physician in the Harvard Radiation Oncology Program at Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Boston Children's Hospital. Previously, William was an Angier B. Duke Scholar at Duke University where he completed his undergraduate studies in Biomedical Engineering, Electrical and Computer Engineering, and Physics and was named to the 2006 All-USA College Academic First Team by USA Today. He then completed a Masters in Chemistry at the University of Oxford in 2008 on a Rhodes Scholarship. Upon returning stateside, he enrolled in the Harvard-MIT MD/PhD program on a NIH Medical Scientist Training Grant and Soros Fellowship, earning his PhD in Biophysics and graduating summa cum laude from Harvard Medical School. William's research focuses on developing and applying single-cell and spatial omics technologies to patient specimens, three-dimensional organotypic models, and genetically-engineered mouse models to elucidate the tumor-stromal crosstalk in gastrointestinal malignancies, with a particular focus on the neural and immune components of pancreatic cancer. In July 2020, William will be joining the faculty at Harvard Medical School/Massachusetts General Hospital as an Instructor in Radiation Oncology.
                        • Arutha Kulasinghe, PhD
                          Peter Doherty NHMRC Early Career Fellow at the Queensland University of Technology (QUT)
                          Biography
                            Dr Arutha Kulasinghe completed his PhD in 2017 at the Queensland University of Technology (QUT). In 2019, Dr Kulasinghe began a Peter Doherty NHMRC Early Career Fellowship to develop predictive biomarkers of immunotherapy response in head and neck and lung cancers. Dr Kulasinghe aims to spatially map these tumours to understand the tumour/immune contexture using novel digital spatial mapping technology. This data may be a powerful tool to determine a personalised course of treatment for individual cancer patients. Dr Kulasinghe is supported by a number of funding agencies including the NHMRC, Cure Cancer, Can Too Foundation, Translational Research Institute (TRI), Princess Alexandra Research Foundation (PARF) and the Garnett Passe and Rodney Williams Memorial Foundation (GPRWMF) and has published his work in over 25 Cancer/Oncology journals with multiple invited National/International presentations. More recently, he's been awarded a 'Scholar-in-Training' award to present at AACR 2020. Twitter: @aruthak
                          • Dana Mustafa, PhD
                            Assistant Professor, Group Leader of the Tumor Immuno-Pathology (TIP) Laboratory, Erasmus University Medical Center
                            Biography
                              Dana Adel Mustafa is a biologist and a cancer researcher at Erasmus medical Center, Rotterdam, The Netherlands. She mainly studies two of the most deadly cancers: pancreatic cancer and brain tumors. Her research aims to reveal the immune regulation and infiltration in various types of cancers. In addition, her group focuses in identifying circulating biomarkers for detecting the response to therapy. She is interested in cancer metabolism, and in connecting the metabolic and genomics maps. She has been using various -omics technologies to identify the new prevention targets. Following by the state-of-the-art organ-on-a chip and organoid models to validate the usefulness of the new discoveries. Working with and for people like patients and students is dr. Mustafa's drive. Therefore, she became an assistant professor and a group leader of the Tumor Immuno-Pathology (TIP) lab in 2017. She became a member of a big consortium of Oncolytic Viro-Immune therapy (OVIT) to create new therapeutic options for cancer patients. Dr. Mustafa strongly believe that we can make progress in the battle against this disease by extensive collaboration between various people, disciplines and institutions.
                            • Peter Nelson, MD
                              Professor of Medicine at the University of Washington
                              Biography
                                Peter Nelson, MD is a Member of the Divisions of Human Biology and Clinical Research at the Fred Hutchinson Cancer Research Center and Professor of Medicine at the University of Washington.
                              • Erin Piazza, PhD
                                Senior Bioinformatics Scientist, NanoString Technologies
                                Biography
                                  Erin Piazza is the lead scientist for gene expression panel development at NanoString. She received her PhD from Stanford University in Cancer Biology, where she studied the final member of the tubulin superfamily in Xenopus and investigated genes differentially expressed during ciliogenesis in mouse. Erin joined NanoString in fall 2015 and enjoys mixing her deep background in oncology with her love of solving problems computationally.
                                • Noemi Reguart, MD, PhD
                                  Thoracic Oncology Consultant, Hospital Clínic de Barcelona
                                  Biography
                                    Dr. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. Dr. Reguart gained a PhD focusing on molecular lung cancer biology at the Molecular Biology Laboratory at Hospital Germans Trias i Pujol, Barcelona and the General Thoracic Surgery and Oncology Laboratory, at the University of California San Francisco (UCSF). She has practiced as a Consultant Oncologist at the Department of Medical Oncology in Hospital Clinic Barcelona since 2008. She is a Clinical Professor at the University of Barcelona, deeply committed to under- and postgraduate teaching. Most recently Dr. Reguart has been designated the lead of the Thoracic Oncology Unit at the Hospital Clínic. Throughout her career, Dr. Reguart has shown her interest in addressing lung cancer. She has been involved in the design and patient recruitment to many personalized lung cancer trials. In addition to clinical practice and patient care, she also conducts basic research with a special interest in lung cancer biomarkers and the identification of predictors of therapy response at the Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory in August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona. She has always maintained an active research interest in her own laboratory as well as through several national and international collaborations. Dr. Reguart is an active member of several international organizations including the Lung Cancer Group of the European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC). She is a member of the Board of Directors of the Spanish Lung Cancer Group (SLCG) since 2007, and is the author of over 80 scientific publications with an H-Score of 38.
                                  • Sergio Rutella, MD, PhD, FRCPath
                                    Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University
                                    Biography
                                      Sergio Rutella, MD PhD, is a licensed hematologist and Fellow of the Royal College of Pathologists with a long-standing interest in leukemia immunobiology and immunotherapy. Sergio is currently the Professor of Cancer Immunotherapy at Nottingham Trent University, United Kingdom. His research focuses on visualizing the state of cancer-immune interactions in patients with acute leukemia, on immune biomarker discovery and on therapeutic strategies to revert cancer-induced immune suppression with the aim to guide treatment choices and improve clinical outcome.
                                    • Lisa Ryden, MD, PhD
                                      Professor i Kirurgi, Lund University, Medical Faculty, dept of Clinical Sciences Lund, div of Oncology and Surgery
                                      Biography
                                        Lisa Rydén is full professor in Surgery at Lund University and a senior consultant in general surgery at Skåne University Hospital. She was a board member of the strategic cancer area BioCare at Lund University 2012-2019 and is currently a board member of Lund University Cancer Centre. She was appointed a Skou Honarary Professor in cancer research at Århus University, Denmark, in 2019. Lisa Rydén wrote her thesis on tamoxifen response in primary breast cancer focusing on predictive tumour features and the work paved the way for forthcoming research in clinically relevant areas of molecular biology. She has been heading a translational research group in breast cancer since 2010 focusing on the importance of tumour progression and prediction of lymph node metastasis. Seven PhD students have graduated based on the program which has been funded by the Swedish Cancer Society and Swedish Research Council among others. She has contributed with > 100 peer-reviewed publications in the field. In 2016 she was awarded the Nordic Medicine Prize in breast cancer research together with Heikki Juensuu and in 2019 Reutersköld´s award in surgical sciences from the Swedish Medical Association. Lisa Rydén held the chair of the South Swedish Breast Cancer group between 2009-2018 and was the secretary of the Swedish Breast Cancer Group 2007-2018. In 2015-2019 she also held the chair of the Swedish Society of Breast Surgeons. In all these positions she encouraged and initiated multidisciplinary and translational collaborations aiming at improving breast cancer care and ultimately the outcome and well-being of breast cancer patients. She is also a collaborative member of Early Breast Cancer Trialists' Collaborative Group and International Breast cancer Intervention Study Group.
                                      • Melanie Spears, PhD
                                        Principal Research Scientist at Ontario Institute for Cancer Research
                                      • E. Aubrey Thompson, PhD
                                        Professor of Cancer Biology, Mayo Clinic Comprehensive Cancer Center
                                        Biography
                                          Dr. Thompson's primary focus is clinical and translational research. His team uses genomic technology and functional genomic tools to elucidate the mechanisms that underlie malignant transformation and may ultimately identify new therapeutic targets or biomarkers of therapeutic response. The team's primary focus is on breast cancer, although the tools and technologies the team has developed are also applied to lung, thyroid, renal and pancreatic cancers. The research interests of E. Aubrey Thompson, Ph.D., involve gene structure and function and control of gene expression as it applies to regulation of cell proliferation, differentiation and death.
                                        • Jon Zugazagoitia, MD, PhD
                                          Physician Scientist, Department of Medical Oncology, Lung Cancer Unit
                                          Biography
                                            I am a physician-scientist focused in lung cancer. I earned an MD degree from the University of Navarra School of Medicine (2007) and I was trained as a resident in medical oncology at Hospital Clinico San Carlos in Madrid (2008-2012). I attained a Ph.D. degree in 2014 working in predictors of BRCA1/2 mutations in women with early-onset breast cancer. I gained extensive training in the methodology of clinical research in lung cancer under the supervision of Luis Paz-Ares (2015-2017). In 2017, I moved to the prestigious laboratory of Dr. Rimm at Yale (New Haven, USA) as a post-doctoral scientist, where I acquired expertise in immunotherapy biomarker science and immunobiology. In 2019, I moved back to my home institution in Madrid (Hospital 12 de Octubre) as a faculty member and independent investigator. My research interests are focused on biomarker science and development of precision immunotherapy strategies for patients with lung cancer.
                                          Posters

                                          No. 1 Molecularly Guided Digital Spatial Profiling for Highly Multiplexed Analysis of Gene Expression with Spatial and Single Cell Resolution
                                            Presenter: Dan Zollinger, NanoString Technologies

                                          Authors: Anushka Dikshit, PhD; Chris Merritt, PhD; Jamie Rose Kuhar; Karen Nyugen; Kristina Sorg; Bingqing Zhang; Courtney M. Anderson, PhD; Xiao-Jun Ma

                                          No. 2 Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors
                                            Presenter: Sarah E. Church, NanoString Technologies

                                          Authors: Sarah E. Church, PhD; Jason W. Reeves; Daniel R. Zollinger; Jill McKay-Fleisch; Andrew M. White, BSc; Michael D. Bailey; Arya Bahrami, PhD; Chris Merritt, PhD; Margaret Hoang; Sarah Warren, PhD; Joseph M. Beechem, PhD

                                          No. 3 Transcriptomic Characterization of Immune Response within Diverse Tumor Environments using the NanoString® nCounter® PanCancer IO 360™ Assay
                                            Presenter: Jessie Perez, NanoString Technologies

                                          Authors: TBC

                                          No. 4 Genomic Characterization of Breast Cancer Heterogeneity using Breast Cancer 360™
                                            Presenter: Yuqi Ren, NanoString Technologies

                                          Authors: Heather Ann Brauer, Yuqi Ren, Lei Yang, Jeremy Force, Dave Henderson, and Sean Ferree

                                          No. 5 Using Multi-omic Profiling to Unravel the Complexity of Triple-Negative Breast Cancer (TNBC)
                                            Presenter: Heather Ann Brauer, NanoString Technologies

                                          Authors: Goel S, Brauer H, Ren Y, Gorman K, Osmani W, Pittenger J, Andrews C, Richardson ET III, Mittendorf EA, Winer EP, Schnitt S, Tolaney SM.

                                          No. 6 Enabling Pathway Analysis of RNA Expression in Formalin-Fixed Paraffin Embedded Tissues with the GeoMx™ DSP Platform
                                            Presenter: Jason Reeves, NanoString Technologies

                                          Authors: Tressa Hood, Jason Reeves, Zach Norgaard, Margaret Hoang, Sarah Warren, Erin Piazza, Rich Boykin, Joseph Beechem

                                          No. 7 Updating Immune Cell Deconvolution for the Spatial Genomics Era
                                            Presenter: Patrick Danaher, NanoString Technologies

                                          Authors: Patrick Danaher, Sarah Church, Chris Merritt, Dan Zollinger, Jason Reeves, Youngmi Kim, Joseph Beechem

                                          No. 8 Fusion Gene Detection in Cell-free Plasma by NanoString Low Input Fusion assay
                                            Presenter: Alan Huan

                                          Authors: TBC

                                          Sponsored by

                                          About Us

                                           

                                           

                                           

                                           

                                          About NanoString Technologies, Inc.

                                          NanoString Technologies is a leading provider of life science tools for translational research. The company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 3,200 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. For more information, please visit www.nanostring.com.

                                           

                                          Help

                                          General LabRoots Questions

                                          email support@labroots.com  

                                          Virtual Events and Webinars

                                          Supported Configurations

                                          • Operating System Internet Explorer Firefox Chrome Safari
                                            Vista IE8+ FF10+ Chrome15+
                                            Windows 7 IE8+ FF10+ Chrome15+
                                            Windows 8 IE10 FF10+ Chrome15+
                                            Mac OS X   FF10+ Chrome15+ Safari5.1+
                                          • Cookie settings: session cookies enabled
                                          • Browser configuration must have JavaScript enabled
                                          • Adobe Flash player 10.2 or later

                                          To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                          Internet Connection

                                          • A minimum of 100Kbps is recommended for audio-only events
                                          • A minimum of 300Kbps is recommended for speaker on-video events

                                          Computer Equipment

                                          • Screen Resolution: Minimum 1024x768
                                          • Video Card: 65,000 colors minimum
                                          • Sound card and speakers (or headphones) for hearing webcast in full format
                                          • Audio Card: 16-bit minimum
                                          • RAM: 512MB of free RAM

                                          Firewall Protocol

                                          • HTTP on port 80 or HTTPS on port 443
                                          • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                          • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                          Work-At-Home Attendees

                                          • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                          For A Seamless Experience

                                          When using a mobile device, FREE Mobile Apps are available:

                                          - For viewing Webinars:

                                          - For viewing Virtual Events

                                          Attendee Guide

                                          • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                          Virtual Event and Webinar Support:

                                          Continuing Education (CME/CE) Support

                                          Show Resources
                                          Attendees
                                          • See more